04th week of 2013 patent applcation highlights part 42 |
Patent application number | Title | Published |
20130023474 | COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders. | 2013-01-24 |
20130023475 | C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS - The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor. In addition, members of this group of molecules may useful for treating or preventing the development of neurodegenerative diseases like general dementia, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis and initiating recovery from traumatic brain injury and spinal cord trauma. These peptides and peptidomimetics may be therapeutically useful whenever increased neurotrophic activity would be clinically advantageous. | 2013-01-24 |
20130023476 | Pharmaceutical Preparation Comprising Recombinant HCG - Preparations including recombinant hCG (r hCG). | 2013-01-24 |
20130023477 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers. | 2013-01-24 |
20130023478 | AQUARETIC AND NATRIURETIC POLYPEPTIDES LACKING VASODILATORY ACTIVITY - This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal. | 2013-01-24 |
20130023479 | USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY - The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis. | 2013-01-24 |
20130023480 | Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream - Purified Bowman-Birk protease inhibitor (BBI) proteins recovered from a soy processing stream are disclosed, as well as a process for recovering and isolating purified BBI proteins from a soy processing stream. | 2013-01-24 |
20130023481 | Adenovirus E1A Fragments for Use in Anti-Cancer Therapies - The present invention relates to an improved cancer therapy comprising co-administration with the E1A 1-80 transcription-repression domain activity. In addition, E1A 1-80 can act as a monotherapy against cancers that express elevated HER2/Neu or in combination with anti-HER2/Neu, chemo- or radiotherapeutic treatments. | 2013-01-24 |
20130023482 | CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF - The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders. | 2013-01-24 |
20130023483 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY - Specific template-fixed β-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are α-amino acid residues connected from the carbonyl (C═O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells. | 2013-01-24 |
20130023484 | PERIPHERIN-SPECIFIC AUTOANTIBODIES AS A MARKER FOR NEUROLOGICAL AND ENDOCRINOLOGICAL DISEASE - The present invention provides for methods and materials for detecting a peripherin-specific autoantibody, which can be associated with neurological and endocrinological disease. | 2013-01-24 |
20130023485 | PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS - The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids, b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two sequences in (a), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a); and a solubility enhancer; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition. | 2013-01-24 |
20130023486 | PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF - The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, | 2013-01-24 |
20130023487 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION - Compounds from 14 Kenyan plants, including from the root of | 2013-01-24 |
20130023488 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE - Compounds and compositions for reducing intracellular lipid accumulation in a cell are described herein. These compounds are useful for the treatment and prevention of lipid/glycogen disorders, as well as for the treatment and prevention of obesity. A high throughput screen for identifying compounds that reduce intracellular lipid accumulation in cells is also provided. | 2013-01-24 |
20130023489 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AND ENVIRONMENTALLY INDUCED HEALTH DISORDERS - Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, including an Onaway potato cultivar optionally complemented by a Russet Burbank, Purple Valley or Bora Valley cultivar. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity. | 2013-01-24 |
20130023490 | TOPICAL FORMULATIONS COMPRISING 1-N-ARYLPYRAZOLE DERIVATIVES AND AMITRAZ - The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs. | 2013-01-24 |
20130023491 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE - In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK). | 2013-01-24 |
20130023492 | PHARMACEUTICAL COMPOSITIONS COMPRISING PLANT-BASED POLYSACCHARIDES AND USES THEREOF - A composition for providing relief to a discomfort of an eye comprises a pharmaceutically acceptable carrier and a polysaccharide extracted from a plant source. In certain embodiments, such a polysaccharide can be extracted from mushrooms, such as from the | 2013-01-24 |
20130023493 | ANDROGRAPHIS PANICULATA EXTRACT - An extract of | 2013-01-24 |
20130023494 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. | 2013-01-24 |
20130023495 | USES OF DGAT1 INHIBITORS - The present invention relates to the use of a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising a DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, for the prevention, delay of progression or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. | 2013-01-24 |
20130023496 | Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer - The present invention discloses a novel combination therapy for HIV-1 treatment relying on a combination of at least one CCR5 antagonist, at least one HIV-1 protease inhibitor and at least one pharmacokinetic enhancer of said at least one CCR5 antagonist and/or at least one HIV-1 protease inhibitor. The combination is intended for use in oral treatment of a disorder selected from the group consisting of HIV-1 infection, retroviral infections genetically related to HIV and AIDS, in a treatment-naïve patient infected with CCR5 tropic HIV-1 virus. | 2013-01-24 |
20130023497 | Triazine Derivatives and their Therapeutical Applications - The present invention comprises inter alia triazine compounds as shown in formula (I) and pharmaceutically acceptable salts thereof. | 2013-01-24 |
20130023498 | MicroRNA Modulators and Method for Identifying and Using the Same - The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease. | 2013-01-24 |
20130023499 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF - Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B-cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2013-01-24 |
20130023500 | CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula: | 2013-01-24 |
20130023501 | PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE - A substantially anhydrous, topical pharmaceutical composition comprising a non-alcoholic three-component solvent mixture and a biologically active vitamin D derivative or analogue dissolved therein as well as a pharmaceutically acceptable carrier may be used in the treatment of dermal conditions. | 2013-01-24 |
20130023502 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS - The invention relates to new substituted pyridinyl-pyrimidines of formula | 2013-01-24 |
20130023503 | NK1 ANTAGONISTS | 2013-01-24 |
20130023504 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways - A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2. | 2013-01-24 |
20130023505 | METHODS FOR INHIBITING PRETERM LABOR AND UTERINE CONTRACTILITY DISORDERS AND PREVENTING CERVICAL RIPENING - The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone. | 2013-01-24 |
20130023506 | METHOD FOR TREATING UTERINE FIBROIDS - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 2013-01-24 |
20130023507 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 2013-01-24 |
20130023508 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 2013-01-24 |
20130023509 | HYALURONIC ACID BASED COPOLYMERS - Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof. | 2013-01-24 |
20130023510 | ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME - The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments. | 2013-01-24 |
20130023511 | ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS - This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity. | 2013-01-24 |
20130023512 | Compositions for Combating Beta-Lactamase-Medicated Antibiotic Resistance Using Beta-Lactamase Inhibitors Useful For Injection - The invention describes a composition for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitor useful for injection, capable of pharmaceutical application. The invention relates to pharmaceutical composition containing ceftriaxone (normally as ceftriaxone sodium) and sulbactam (normally as sulbactam sodium). Such compositions are found to be useful for intramuscular or intravenous administration as antibiotics for hospitalized patients with serious infections. Specifically, this invention relates to a pharmaceutical composition further including an aminocarboxylic acid chelating agent, for example, ethylenediaminetetraacetic acid (EDTA), or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of this invention have been found normally to enhance resistance to particulate formation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention also gives a process to manufacture these compositions. The invention gives a method of treating a subject having a condition or disorder, wherein a treatment with ceftriaxone sodium and sulbactam sodium is indicated. | 2013-01-24 |
20130023513 | Methods and Compositions for Treating Cardiovascular Disorders - The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis. | 2013-01-24 |
20130023514 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS - The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents. | 2013-01-24 |
20130023515 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 2013-01-24 |
20130023516 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 2013-01-24 |
20130023517 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists - Object of the present invention are novel substituted compounds of the formula 1, | 2013-01-24 |
20130023518 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES - A compound of formula (I) | 2013-01-24 |
20130023519 | 5-ALKYNYL-PYRIDINES - 5-alkynyl-pyridine of general formula (I) | 2013-01-24 |
20130023520 | ANAESTHETIC EYE SOLUTION AND METHOD OF USE - An eye drop solution includes an anaesthetic and at least one medicament. The anaesthetic is preferably provided in a range of from about 0.001% to about 1.0%. The eye drop solution may further include either a lubricant or a preservative, or both of these. | 2013-01-24 |
20130023521 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS - The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use. | 2013-01-24 |
20130023522 | BENZAMIDES - Novel benzamide derivatives of formula (I) | 2013-01-24 |
20130023523 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 2013-01-24 |
20130023524 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT - Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R | 2013-01-24 |
20130023525 | GYRASE INHIBITORS AND USES THEREOF - The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. | 2013-01-24 |
20130023526 | Isoxazolines as Therapeutic Agents - The present invention provides compound of Formula (I) | 2013-01-24 |
20130023527 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia - The present invention relates to certain | 2013-01-24 |
20130023528 | PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE - Compounds for inhibiting hypoxia inducible factor (HIF) prolyl-4-hydroxylases (PHDs) having the general formula (1). Methods of using these and related compounds for treating a patient having a condition that would benefit from inhibiting HIF PHD are also described herein. | 2013-01-24 |
20130023529 | Methods Involving Aldose Reductase Inhibitors - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma. | 2013-01-24 |
20130023530 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS - The present invention is directed to novel compounds of formula I | 2013-01-24 |
20130023531 | PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS - The present invention encompasses compounds of general formula (I) | 2013-01-24 |
20130023532 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS - Disclosed are compounds having the formula: or a salt thereof, wherein A, n, R | 2013-01-24 |
20130023533 | NEW 5-ALKYNYL-PYRIDINES - 5-alkynyl-pyridine of general formula (I) | 2013-01-24 |
20130023534 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS - Disclosed are compounds having the formula (I): wherein Z, n, R | 2013-01-24 |
20130023535 | METHOD OF PREVENTING AND/OR TREATING DIABETIC NEUROPATHY - The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying). Further, the invention is particularly useful for providing an agent for improving pathophysiology of diabetic neuropathy. | 2013-01-24 |
20130023536 | FIXED DOSE COMBINATION OF BIMATOPROST AND BRIMONIDINE - The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma | 2013-01-24 |
20130023537 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES - The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim | 2013-01-24 |
20130023538 | Heteroaryl Derivatives as CFTR Modulators - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-01-24 |
20130023539 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) - The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases. | 2013-01-24 |
20130023540 | TREATMENT OF MASTITIS - The invention relates to the simplified treatment of mastitis with enrofloxacin or ciprofloxacin, in particular in the case of cows. | 2013-01-24 |
20130023541 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS - The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases. | 2013-01-24 |
20130023542 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2013-01-24 |
20130023543 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2013-01-24 |
20130023544 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING - The invention therefore relates to compounds of the formula I | 2013-01-24 |
20130023545 | CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES - The present invention relates to cycloalkyloxycarboxylic acid derivatives of the formula I | 2013-01-24 |
20130023546 | THIENOPYRIMIDINE DERIVATIVES - This invention provides thienopyrimidine derivatives of the formula, | 2013-01-24 |
20130023547 | DISPERSIBLE TABLET - The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide. | 2013-01-24 |
20130023548 | Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes. | 2013-01-24 |
20130023549 | Pharmaceutical Compositions Comprising Nilotinib or Its Salt - A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process. | 2013-01-24 |
20130023550 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME - Pharmaceutical compositions that include about 10 mg pazopanib/mL of the composition and about 2 to about 13% w/w of a modified cyclodextrin as well as methods of making the same are described. | 2013-01-24 |
20130023551 | DISPIRO TETRAOXANE COMPOUNDS - A compound having the formula (I) | 2013-01-24 |
20130023552 | Small molecules with antimalarial activity - The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria. | 2013-01-24 |
20130023554 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 2013-01-24 |
20130023555 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE - 4-Amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide which inhibits protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved aqueous solubility profile, compositions containing 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide and methods of treating diseases using 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide are disclosed. | 2013-01-24 |
20130023556 | AUTOTAXIN INHIBITORS - The present invention relates to compounds according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers. | 2013-01-24 |
20130023557 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-B]PYRIDINE RING - The invention therefore relates to compounds of the formula I | 2013-01-24 |
20130023558 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-c]PYRIDINE RING - Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring | 2013-01-24 |
20130023559 | ALCOHOL FREE FORMULATION OF ARGATROBAN - An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine. | 2013-01-24 |
20130023560 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRON TOXICITY - Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl- | 2013-01-24 |
20130023561 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof - The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers. | 2013-01-24 |
20130023562 | NOVEL PIPERIDINE DERIVATIVES - The present invention provides a compound of a formula (I): | 2013-01-24 |
20130023563 | AMIDINOANILINE DERIVATIVE - Provided are a novel amidine derivative having an activated blood coagulation factor X inhibitory activity, a production method thereof, a production intermediate therefor, and a pharmaceutical composition containing the amidine derivative. An amidinoaniline derivative represented by the following formula (1-1) or a pharmaceutically acceptable salt thereof: | 2013-01-24 |
20130023564 | PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes the compound of formula (I): | 2013-01-24 |
20130023565 | INFLUENZA A 2009 PANDEMIC H1N1 POLYPEPTIDE FRAGMENTS COMPRISING ENDONUCLEASE ACTIVITY AND THEIR USE - The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase possessing endonuclease activity, wherein said PA subunit is from Influenza A 2009 pan-demic H1N1 virus or is a variant thereof. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds which are able to modulate, preferably to inhibit, the endonuclease activity of the PA subunit polypeptide fragment or variant thereof of the present invention and pharmaceutical compositions comprising said compounds for the treatment of disease conditions caused by viral infections with viruses of the | 2013-01-24 |
20130023566 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES - The invention relates to 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives having the general Formula (I) wherein R | 2013-01-24 |
20130023567 | Novel Compounds - A compound for use in the treatment of proliferative disorders, such as cancer, having the following formula: | 2013-01-24 |
20130023568 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses - The present invention relates to benzimidazole derivatives and their pharmaceutical compositions and uses, specifically to benzimidazole derivatives of Formula (I), or their stereoisomer, pharmaceutically acceptable salt or solvates thereof, in which R | 2013-01-24 |
20130023569 | Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders - There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject. | 2013-01-24 |
20130023570 | POLYMORPHS OF DARUNAVIR - The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 2013-01-24 |
20130023571 | N- ( 4-PERFLUOROALKYL-PHENYL) -4-TRIAZOLYL-BENZAMIDES AS INSECTICIDES - The present invention relates to novel triazole-substituted benzamide derivatives, to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them. Formula (I). | 2013-01-24 |
20130023572 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING SKIN DISEASES - The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. | 2013-01-24 |
20130023573 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE - The present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the alpha 2 adrenergic receptors. | 2013-01-24 |
20130023574 | METHOD FOR GENERATING DATA SET FOR INTEGRATED PROTEOMICS, INTEGRATED PROTEOMICS METHOD USING DATA SET FOR INTEGRATED PROTEOMICS THAT IS GENERATED BY THE GENERATION METHOD, AND METHOD FOR IDENTIFYING CAUSATIVE SUBSTANCE USING SAME - Provided are a method for generating a data set for integrated proteomics analysis, whereby expression level variations of both of proteins and genes can be integrally united together and, moreover, highly accurate and appropriate analysis results can be obtained compared with the existing cases where the expression variation amount of proteins or genes is singly analyzed, an integrated proteomics analysis method, a method for identifying a protein causative of a disease or the like using these methods, and a method of using the same???. The aforesaid method for generating a data set for integrated proteomics analyses comprises: a protein identity number-assigning step for assigning common identity numbers to the expression variation amount data of individual proteins; a gene identity number-assigning step for assigning common identity numbers to the expression variation amount data of individual genes; a data-binding step for binding together the set of the expression variation amount data; a data-rejecting step for rejecting, among the individual expression variation amount data constituting the thus bound data set, data showing a p-value equal to or greater than a specific level; and a data-selecting step for selecting one data, from a set of data having the same common identity number assigned thereto, on the basis of a definite requirement to thereby generate the data set to be subjected to integrated proteomics analyses. Further, the data set for integrated proteomics analyses thus generated is subjected to GO analysis and network analysis to thereby identify a protein causative of a disease, a pathological condition or the like. Furthermore, the causative protein thus identified is usable, for example, a tumor marker or a clinical target. | 2013-01-24 |